NCT06336902 2026-03-17
Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer
University of Southern California
Phase 1 Recruiting
Clinical Trials
37 trialsNCT07152821 2026-03-10
BATTMAN
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT06279130 2026-03-05
NEOASIS
The Netherlands Cancer Institute
Phase 2/3 Recruiting
NCT06346197 2026-03-02
CIME
Centre Leon Berard
Phase 3 Recruiting
NCT07193862 2026-02-27
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
Northwell Health
Phase EARLY_PHASE1 Recruiting
NCT05928806 2026-02-11
ARCITECT
Hoosier Cancer Research Network
Phase 2 Suspended
NCT05672316 2026-01-28
Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT04028063 2026-01-27
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
University of Colorado, Denver
Phase 2 Recruiting
NCT06589440 2026-01-15
Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Stingray Therapeutics
Phase 2 Recruiting
NCT05363709 2026-01-14
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06076837 2026-01-12
The Seven Trial: Exploiting the Unfolded Protein Response
HonorHealth Research Institute
Phase 1 Active not recruiting
NCT06411691 2025-12-18
KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Recruiting
NCT06782932 2025-12-03
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Recruiting
NCT06251973 2025-12-02
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06843434 2025-12-02
A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05627635 2025-11-10
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT05205330 2025-10-29
Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers
Rottapharm Biotech
Phase 1/2 Active not recruiting
NCT06843551 2025-08-14
EMPIRE
University of Miami
Phase 2 Recruiting
NCT03104699 2025-07-30
A Study of AGEN2034 in Advanced Tumors and Cervical Cancer
Agenus Inc.
Phase 1/2 Completed
NCT05571293 2025-07-30
NEST-1
Weill Medical College of Cornell University
Phase 2 Suspended
NCT06780787 2025-06-26
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery
City of Hope Medical Center
Phase 2 Recruiting
NCT05891821 2025-05-08
Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)
Immune Oncology Research Institute
Phase 2 Recruiting
NCT06322108 2025-05-08
Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)
Immune Oncology Research Institute
Phase 2 Recruiting
NCT05377528 2025-04-30
Study of AGEN1571 in Participants With Advanced Solid Tumors
Agenus Inc.
Phase 1 Completed
NCT05572970 2025-04-30
Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)
Agenus Inc.
Available
NCT06300463 2025-04-06
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT03894215 2025-02-20
RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
Agenus Inc.
Phase 2 Active not recruiting
NCT03860272 2025-02-06
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus Inc.
Phase 1 Active not recruiting
NCT06782555 2025-01-21
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
ImmunoGenesis
Phase 1/2 Recruiting
NCT06751524 2024-12-30
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
Agenus Inc.
Available
NCT05638698 2024-09-23
TESLA
University of Kansas Medical Center
Phase 2 Active not recruiting
NCT04430036 2024-04-04
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Terminated
NCT05033132 2024-03-28
A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer
Agenus Inc.
Phase 2 Withdrawn
NCT03495882 2023-07-05
Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)
Agenus Inc.
Phase 1/2 Completed
NCT05561491 2023-06-22
A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients
Targovax ASA
Phase 2 Withdrawn
NCT04943627 2022-10-05
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
Agenus Inc.
Phase 3 Withdrawn
NCT04607200 2022-01-11
AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
Agenus Inc.
Phase 2 Withdrawn